ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

NUVL Nuvalent Inc

83.45
-4.65 (-5.28%)
19 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Nuvalent Inc NASDAQ:NUVL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -4.65 -5.28% 83.45 1.88 88.92 88.04 82.535 87.87 395,984 01:00:00

Nuvalent to Participate in the Piper Sandler 36th Annual Healthcare Conference

26/11/2024 11:52am

PR Newswire (US)


Nuvalent (NASDAQ:NUVL)
Historical Stock Chart


From Dec 2024 to Dec 2024

Click Here for more Nuvalent Charts.

CAMBRIDGE, Mass, Nov. 26, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 3:30 p.m. ET in NYC.

Nuvalent, Inc. (PRNewsfoto/Nuvalent, Inc.)

A live webcast will be available in the Investors section of the company's website at www.nuvalent.com, and archived for 30 days following the presentation.

About Nuvalent
Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference-302316455.html

SOURCE Nuvalent, Inc.

Copyright 2024 PR Newswire

1 Year Nuvalent Chart

1 Year Nuvalent Chart

1 Month Nuvalent Chart

1 Month Nuvalent Chart

Your Recent History

Delayed Upgrade Clock